Sex differences in cerebral blood flow regulation and Alzheimer's disease: Mechanistic insights and opportunities for precision pharmacology
Advances in Translational Research · 2026
DOI: 10.1556/1661.2025.00103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Translational Research, 2026. Verfasst von Andrew Gregory und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 360 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, TRIBA Faculty Startup Fund from Augusta University, American Heart Association, Canadian Institutes of Health Research.
Themen: Demenz
Abstract (Originalsprache)
Biological sex is an under recognized determinant of cerebrovascular physiology with direct implications for therapeutic development in Alzheimer's disease (AD). Emerging evidence shows that sex-specific hormonal, genetic, epigenetic, and structural factors shape key regulatory mechanisms of cerebral blood flow (CBF)—including myogenic reactivity, endothelial signaling, neurovascular coupling, and metabolic vasoregulation. Estrogen enhances nitric oxide and epoxyeicosatrienoic acid (EET)–mediated vasodilation, stabilizes endothelial and smooth-muscle Ca 2+ signaling, and preserves neurovascular coupling; its abrupt loss after menopause accelerates arterial stiffening, impairs autoregulation, and increases susceptibility to hypoperfusion-related neurodegeneration. Testosterone and progesterone exert distinct and dose-dependent cerebrovascular effects, influencing baseline tone, inflammatory signaling, and small-vessel vulnerability in males and females. Sex-dependent interactions with key AD-related pathways—including APOE genotype, amyloid and tau accumulation, oxidative stress, and blood–brain barrier dysfunction—further contribute to divergent perfusion trajectories and clinical manifestations. Despite these mechanistic insights, sex remains insufficiently integrated into biomarker development, target validation, and therapeutic trial design. Incorporating sex-specific cerebrovascular phenotypes may refine the use of imaging modalities (ASL-MRI, PET), enhance the development of CBF-modulating agents (e.g., sEH inhibitors, 20-HETE pathway modulators, endothelial-targeted therapies), and support precision approaches to hormone-based or vascular-targeted interventions. Understanding how biological sex influences CBF regulation across the lifespan is essential for advancing vascular-focused drug discovery and improving individualized therapeutic strategies for AD.
Förderung
- National Institutes of Health, TRIBA Faculty Startup Fund from Augusta University
- American Heart Association
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Ontario Ministry of Colleges and Universities
- Canada Research Chairs Program
Zitieren
APA
Gregory, A., Wang, S., Morgan, G. C., Hanscom-Trofy, Y., Liu, Y., Swardfager, W., & Fan, F. (2026). Sex differences in cerebral blood flow regulation and Alzheimer's disease: Mechanistic insights and opportunities for precision pharmacology. Advances in Translational Research. https://doi.org/10.1556/1661.2025.00103
Vancouver
Gregory A, Wang S, Morgan GC, Hanscom-Trofy Y, Liu Y, Swardfager W, et al. Sex differences in cerebral blood flow regulation and Alzheimer's disease: Mechanistic insights and opportunities for precision pharmacology. Advances in Translational Research. 2026. doi:10.1556/1661.2025.00103
BibTeX
@article{Gregory2026,
author = {Gregory, Andrew and Wang, Shaoxun and Morgan, Gilbert C. and Hanscom-Trofy, Yvan and Liu, Yedan and Swardfager, Walter and Fan, Fan},
title = {Sex differences in cerebral blood flow regulation and Alzheimer's disease: Mechanistic insights and opportunities for precision pharmacology},
journal = {Advances in Translational Research},
year = {2026},
doi = {10.1556/1661.2025.00103}
}
EUVIMED